FALCO HOLDINGS Co., Ltd

FALCO HOLDINGS Co., Ltd

TTSE:4671
2,716.00
JPY
-5.00
(-0.18%)
26.13BMarket Cap
Nov 06Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
4,846.99
4,126.87
4,355.74
4,164.32
4,227.64
4,041.13
4,060
4,201.77
4,797.28
4,465.45
3,916.58
4,101.43
4,346.99
- -
Basic EPS, GAAP
189.06
98.94
120.41
133.89
156.09
59.76
116.86
178.54
338.93
215.22
151.72
181.81
201.1
- -
Free Cash Flow per Basic Share
-67.23
30.91
135.69
-41.58
130.25
42.47
73.99
127.57
185.63
67.39
199.62
107.19
128.18
- -
Dividend per Share
24.48
35.34
36.92
38.68
40.93
48.14
47.48
50.1
58.33
67.87
109.37
136.17
130.08
- -
Book Value per Share
1,368.83
1,459.91
1,504.43
1,625.88
1,751.62
1,733.86
1,785.22
1,974.19
2,244.78
2,369.31
2,438.35
2,486.53
2,584.15
- -
Tangible Book Value per Share
1,304.44
1,402.1
1,463.96
1,591.82
1,702.69
1,677.68
1,722.38
1,918.29
2,197.45
2,335.63
2,406.77
2,433.07
2,523.21
- -
Basic Weighted Avg Shares
12
11
11
11
11
11
11
10
10
11
11
11
10
10
Sales/Revenue/Turnover
58,401
46,593
48,727
45,971
45,962
44,156
43,185
43,608
50,007
46,913
43,007
43,313
43,578
- -
Operating Margin (%)
1.91
3.6
4.34
4.67
4.81
3.03
1.95
6
10.99
6.56
5.01
5.39
5.73
- -
Depreciation Expense
1,514
1,040
913
862
878
827
927
953
958
1,041
978
941
1,061
- -
Net Income, GAAP
2,278
1,117
1,347
1,478
1,697
653
1,243
1,853
3,533
2,261
1,666
1,920
2,016
- -
Effective Tax Rate (%)
45.23
40.39
41.72
33.66
36.12
45.72
32.79
35.89
36.54
38.78
35.19
30.86
34.56
- -
Profit Margin (%)
3.9
2.4
2.76
3.22
3.69
1.48
2.88
4.25
7.07
4.82
3.87
4.43
4.63
- -
Working Capital
4,844
6,315
7,164
6,393
7,990
7,625
6,677
11,210
11,279
13,142
11,462
10,796
10,495
- -
LT Debt
1,428
351
460
336
732
535
1,139
3,815
2,791
194
148
978
848
- -
Total Equity
15,772
16,365
16,766
17,664
19,080
19,013
18,892
20,484
23,476
26,589
26,024
25,252
25,868
- -
Return on Invested Capital (%)
2.73
4.95
6.44
7.12
6.57
3.29
2.54
6.7
12.34
6.4
4.91
5.93
5.95
- -
Return on Capital (%)
10.79
5.91
7.29
7.62
8.1
3.02
5.71
7.68
13.17
7.98
5.94
7.19
7.5
- -
Return on Common Equity (%)
15.13
6.95
8.13
8.59
9.24
3.43
6.56
9.41
16.07
9.03
6.33
7.49
7.89
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
400
407
- -
LT Borrowings
759
673
- -
LT Finance Leases
- -
175
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
25,374
26,127
25,707

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
17,790
18,138
- -
Cash, Cash Equivalents & STI
9,049
9,267
- -
Accounts Receivable, Net
5,795
6,205
- -
Inventories
1,571
1,229
- -
Total Current Liabilities
7,744
7,643
- -
Payables & Accruals
- -
- -
- -
ST Debt
400
407
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.6%
5.04%
2.44%
Free Cash Flow
-31.06%
31.5%
13.52%
Net Income, GAAP
15.1%
9.72%
5%
Sales/Revenue/Turnover
-0.94%
0.29%
0.61%
Total Cash Common Dividend
13.78%
22.61%
-9.32%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
43,313
2026
- -
- -
- -
- -
43,578
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
181.81
2026
- -
- -
- -
- -
201.1
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
136.17
2026
- -
- -
- -
- -
130.08
2027
- -
- -
- -
- -
- -

Company Description

CEO
Tadashi Yasuda
Full Time Employees
1,037
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
1-3-7, Uchihiranomachi Chuo-ku Kyoto KY Japan 540-0037
IPO Date
Apr 1, 1997
Business
FALCO HOLDINGS Co., Ltd. primarily engages in the provision of clinical testing and dispensing pharmacy services in Japan. The company offers comprehensive clinical testing services including genetic tests, biochemistry, hematology, pathology, immunology, and microbiology; it also provides genetic testing services. In addition, FALCO develops and markets in vitro diagnostics designed to meet unmet medical needs. The company operates in the dispensing pharmacies and drugstore sector and provides various medical information technology services, including the development and sale of medical chart systems such as HAYATE/NEO, a cloud-based electronic medical chart system for small and medium-sized hospitals, and @home Dr., an electronic medical chart for bedless clinics. FALCO targets medical institutions, healthcare providers, and pharmaceutical sectors primarily in Japan. The company was founded in 1962 and is headquartered in Osaka, Japan. Recent major developments include an equity buyback program completed in 2025 and strategic transactions involving senior debt with companies such as Osisko and Glencore Canada Corporation. These transactions, which involved issuance and exercise of common share purchase warrants, are part of the company's financial restructuring efforts, effective from December 31, 2024. FALCO has also focused on expanding its medical IT services and clinical testing capabilities to further penetrate domestic healthcare markets. The company continues to advance its portfolio in genetic and clinical diagnostics while maintaining a strong presence in pharmacy dispensing and healthcare IT solutions. FALCO operates through business segments that include Clinical Testing, Dispensing Pharmacy, and Medical IT, serving a broad customer base comprising hospitals, clinics, pharmacies, and healthcare companies within Japan. The company’s ongoing strategic emphasis on innovation in diagnostics and technology-enabled healthcare services supports its position in the Japanese medical services industry. It is publicly listed on the Tokyo Stock Exchange under the ticker 4671.T. This description incorporates the latest operational changes and financial strategies of FALCO HOLDINGS Co., Ltd., reflecting its comprehensive product and service offerings along with recent major company events.